Clinical trial · Interventional
Photodynamic Therapy (PDT) in Lung Cancer
An Evaluation of the Effectiveness of Photodynamic Therapy (PDT) Compared to Surgical Resection in Early Stage Roentgenographically Occult Lung Cancer.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being done to determine whether a substance called hematoporphyrin can be used to treat tumors in various locations in the body when used in association with a laser. Hematoporphyrin is a substance that is taken up by cancerous cells. When these cells are exposed to the energy emitted by a laser source, chemical reactions occur in the cell and cause the cells to die. It is hoped that this treatment method may be able to selectively destroy malignant cells without damaging surrounding healthy tissue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PHOTODYNAMIC THERAPY (PDT) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Photodynamic Therapy
- description
- PHOTODYNAMIC THERAPY (PDT)
- interventionNames
- Procedure: PHOTODYNAMIC THERAPY (PDT)
Primary outcomes (1)
- measure
- Evaluate the impact of PDT on these patients by determining the percentage of patients who are spared surgery.
- timeFrame
- 3 years
Secondary outcomes (6)
- measure
- Morbidity,overall mortality and lung cancer mortality.
- timeFrame
- 3 years
- measure
- Rate of subsequent lung cancer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 50 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patient less than 75 years of age. * Squamous cell lung cancer proven by biopsy or repeated Brushings obtained from the same location at separate bronchoscopies. * Occult lung cancer by chest roentgenogram and CT scan If CT scan is abnormal, mediastinoscopy is negative. * Cancer is bronchoscopically superficial as defined in section IV, E. * Estimated size less than 1 cm diameter on the surface of the bronchus with the surface area of 0.7 to 1.0 cm2. * Location in the trachea, main stem bronChi, lobar bronchi, segmental bronchi, or subsegmental bronchi. * Medical condition permits surgery: cardiovascular status is satisfactory for operation and postoperative FEVl is predicted to be greater than 0.75 liter. * Patients will complete quality of life questionnaire and a spirometry which will include forced expiratory volume in 1 second (FEVl) and forced vital capacity (FVC). * On bronchoscopic biopsy, the carcinoma is entirely in situ or shows no more than 2 mm of microinvasion. * The characteristics of the mucosa. may include paleness, opacity, loss of luster, roughness, micro-granularity. * The mucosal folds may demonstrate lack of clarity. thickening, disappearance. * There may be small nodular protrusion of tumor into the lumen * The peripheral extent of tumor invasion can be confirmed endoscopically. Exclusion Criteria: * A medical disease which excludes surgery as an option * A postoperative FEVl predicted to be less than 0.75 liter * A previous carcinoma or other malignancy not curatively treated * The presence of simultaneous lung cancers * CT scan of the chest shows thickening of the bronchial wall or extension beyond the bronchial wall in the area of the cancer
References
Publications (0)
Data not yet available